Glaukos' (GKOS) iDose TR Gets FDA Nod for Glaucoma Treatment
https://www.zacks.com/stock/news/2200160/glaukos-gkos-idose-tr-gets-fda-nod-for-glaucoma-treatment?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2200160
Dec 19, 2023 - The FDA approval of Glaukos' (GKOS) iDose TR is likely to reshape glaucoma care. A micro-invasive breakthrough promises proactive, durable treatment, heralding a new era in eye health.
0
DexCom's (DXCM) G7 CGM Connects With Tandem's Insulin Pump
https://www.zacks.com/stock/news/2200159/dexcom-s-dxcm-g7-cgm-connects-with-tandem-s-insulin-pump?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2200159
Dec 19, 2023 - Dexcom's (DXCM) G7 integrates with Tandem's t:slim X2, revolutionizing diabetes care. A perfect combination of accuracy and innovation, this synergy sets a new standard in continuous glucose monitoring.
0
Masimo's (MASI) Stork Baby Monitoring System Approved by FDA
https://www.zacks.com/stock/news/2200083/masimo-s-masi-stork-baby-monitoring-system-approved-by-fda?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2200083
Dec 19, 2023 - The latest FDA clearance of Masimo's (MASI) Stork smart home baby monitoring system is likely to provide a continuous and accurate view of babies' health data.
0
Here's Why You Should Retain QuidelOrtho (QDEL) Stock for Now
https://www.zacks.com/stock/news/2199972/here-s-why-you-should-retain-quidelortho-qdel-stock-for-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2199972
Dec 19, 2023 - QuidelOrtho's (QDEL) strong product portfolio raises optimism about the stock.
0
Reasons to Add DexCom (DXCM) Stock to Your Portfolio Now
https://www.zacks.com/stock/news/2199515/reasons-to-add-dexcom-dxcm-stock-to-your-portfolio-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2199515
Dec 18, 2023 - DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.
0
ITGR or EW: Which Is the Better Value Stock Right Now?
https://www.zacks.com/stock/news/2199504/itgr-or-ew-which-is-the-better-value-stock-right-now?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_3-2199504
Dec 18, 2023 - ITGR vs. EW: Which Stock Is the Better Value Option?
0
Here's Why You Should Retain Catalent (CTLT) Stock for Now
https://www.zacks.com/stock/news/2198761/here-s-why-you-should-retain-catalent-ctlt-stock-for-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2198761
Dec 15, 2023 - Catalent's (CTLT) products and services portfolio and technology foundation raise optimism about the stock.
0
Why Integer (ITGR) is a Top Value Stock for the Long-Term
https://www.zacks.com/stock/news/2198672/why-integer-itgr-is-a-top-value-stock-for-the-long-term?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_value_score-2198672
Dec 15, 2023 - Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
0
Integer Holdings Corporation (ITGR) Hit a 52 Week High, Can the Run Continue?
https://www.zacks.com/stock/news/2197283/integer-holdings-corporation-itgr-hit-a-52-week-high-can-the-run-continue?cid=CS-ZC-FT-52_week_high-2197283
Dec 13, 2023 - Integer (ITGR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
0
Masimo's (MASI) ORi Favored by Study for PaO2 Information
https://www.zacks.com/stock/news/2196904/masimo-s-masi-ori-favored-by-study-for-pao2-information?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2196904
Dec 12, 2023 - Masimo's (MASI) latest study indicates that ORi can be a valuable tool to provide information on arterial oxygenation even during OLV.
0